<DOC>
	<DOCNO>NCT00115375</DOCNO>
	<brief_summary>PICOLO double blind placebo control phase II dose ranging , dose escalate study patient Blalock-Taussig age category ( neonate infants/toddlers ) , determine dose provide inhibition platelet aggregation similar adult .</brief_summary>
	<brief_title>Platelet Aggregation Inhibition Children Clopidogrel ( PICOLO )</brief_title>
	<detailed_description>There 3 blind dose group 12 patient ( 9 active , 3 placebo ) , central randomization , stratify age ( &lt; 1 month ; 1 24 month ) . There comparison ADP-induced platelet aggregation steady state .</detailed_description>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Neonates infants/toddlers ( 24 month ) risk thrombosis ( e.g. , BlalockTaussig shunt systemic pulmonary artery shunt , Kawasaki disease , vascular stent condition require antiplatelet therapy ) . Ongoing bleed increase risk bleed Weight &lt; 2 kg ; gestational age &lt; 35 week Allergy drug Current plan anticoagulant treatment Unable receive drug enterically Platelet transfusion &lt; 7days Thrombocytopenia Hepatic renal failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>THROMBOSIS</keyword>
	<keyword>PLATELET AGGREGATION</keyword>
	<keyword>Pediatrics</keyword>
</DOC>